Detalhe da pesquisa
1.
Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
BJOG
; 2024 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320967
2.
Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause.
Health Qual Life Outcomes
; 21(1): 126, 2023 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990323
3.
Drug utilization patterns and healthcare resource use and costs in patients with neurogenic bladder in the United Kingdom: A retrospective primary care database study.
Neurourol Urodyn
; 38(5): 1278-1289, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30924184
4.
Clinical outcome of paediatric patients with traumatic brain injury (TBI) receiving 3% hypertonic saline (HTS) in the emergency room of a tertiary care hospital.
J Pak Med Assoc
; 69(11): 1741-1745, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31740892
5.
A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines.
Neurourol Urodyn
; 37(7): 2273-2280, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29664124
6.
A critical appraisal of the principal guidelines for neurogenic lower urinary tract dysfunction using the AGREE II instrument.
Neurourol Urodyn
; 37(8): 2945-2950, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30058737
7.
Development of an overactive bladder assessment tool (BAT): A potential improvement to the standard bladder diary.
Neurourol Urodyn
; 37(5): 1701-1710, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29360189
8.
Does BMI, gender or age affect efficacy/tolerability of solifenacin in the management of overactive bladder?
Int Urogynecol J
; 28(3): 477-488, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27605255
9.
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Int J Clin Pract
; 71(5)2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28419650
10.
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
J Urol
; 196(3): 809-18, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27063854
11.
Pattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit.
J Pak Med Assoc
; 66(8): 961-7, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27524528
12.
Impact of delay in admission on the outcome of critically ill patients presenting to the emergency department of a tertiary care hospital from low income country.
J Pak Med Assoc
; 66(5): 509-16, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27183926
13.
Frequency of metabolic syndrome in psychiatric patients, is this the time to develop a standardized protocol to reduce the morbidity from an acute care psychiatry unit.
J Pak Med Assoc
; 65(1): 54-8, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25831675
14.
Onset of action of the ß3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
World J Urol
; 32(6): 1565-72, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24458878
15.
Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Neurourol Urodyn
; 33(1): 17-30, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24127366
16.
The efficacy and tolerability of the ß3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Age Ageing
; 43(5): 666-75, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24610862
17.
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Int J Urol
; 21(10): 960-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25092441
18.
Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause.
Adv Ther
; 41(6): 2233-2252, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396203
19.
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Menopause
; 31(1): 68-76, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38016166
20.
Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
Adv Ther
; 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775925